RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
Portfolio Pulse from
Ultragenyx's cholesterol drug Evkeeza has received European Commission approval for expanded use in treating young patients aged 6 months to 5 years with a rare cholesterol disorder.
January 07, 2025 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx's drug Evkeeza has been approved by the European Commission for expanded use in young children, potentially increasing its market reach and revenue.
The European Commission's approval for expanded use of Evkeeza in young children could lead to increased sales and revenue for Ultragenyx, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100